* SEK 800m directed share issue completed, 28% dilution * Next step is a rights issue of ~SEK 750m (...
Redeye provides its initial comments on Stille following the Q3 2025 report, which came in below our...
Redeye comments on Litium’s Q3 report, which included a solid organic ARR growth of 11%.
Redeye comments on Evolution’s Q3-results which were weaker than expected, mainly due to lower than ...
* Q3e sales up 14% y-o-y, 7% organic, supported by order intake * Estimate seasonally strong 9.
* Adj. EBITA -6% vs ABGSC, -5% vs ModFin consensus * Org.
Atria reported Q3 adjusted EBIT of EUR 25.4m, 7% above LSEG Data & Analytics consensus.
Redeye is positive about Q-linea’s new cost efficiency program.
We raise adjusted EBITA by 1% for 2026E-27E, following the impressive 80bp y/y margin uplift in Supp...
Redeye was hoping for a bit more in terms of topline, but market demand has been hesitant, particula...
* Q3 EEs 2.7m, down 23% y-o-y, sales SEK 23.5m, down 28% * Softening commercial vehicle market drive...
Redeye updates its estimates and valuation after Relais’ Q3 2025 report.
Flexion has entered into a partnership with Xsolla, a global U.
Consti reports its Q3 results on October 24th. We expect the improved backlog to support continued g...
* '25e-'27e sales cut by 20-14% on sluggish market and delayed orders * Rights issue of ~SEK 87m ann...
